Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00427505
- Lead Sponsor
- Novartis
- Brief Summary
This is a study to investigate the pharmacokinetics of deferasirox
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Good health
- No evidence of iron deficiency
- Weight between 50 and 100 kg
- Body Mass Index between 19 and 29 kg/m2
Exclusion Criteria
- Use of certain drugs, herbal remedies or nutrients
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method To assess the effect of deferasirox on the pharmacokinetics of midazolam
- Secondary Outcome Measures
Name Time Method Safety assessed by adverse events (AEs)